Sentiment-Signal
7,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (05.02.2026)
HOCH Abgang Schlüsselpersonen (05.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 27.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 14.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth by specific reference in such a filing. Item 5.02. Departure of Directors or Certain Officers; Election of Direc |
| 19.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointm |
| 13.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | set forth by specific reference in such a filing. Item 5.02. Departure of Directors or Certain Officers; Election of Dir |
| 08.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 22.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cer |
Stammdaten
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Unternehmen & Branche
| Name | Lexeo Therapeutics, Inc. |
|---|---|
| Ticker | LXEO |
| CIK | 0001907108 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 418,6 Mio. USD |
| Beta | 2,00 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -99,961,000 | -1.86 | 268,688,000 | 246,669,000 | |
| 2025-09-30 | 10-Q | -20,283,000 | -0.33 | 143,844,000 | 120,831,000 | |
| 2025-06-30 | 10-Q | -26,103,000 | -0.60 | 176,068,000 | 138,218,000 | |
| 2025-03-31 | 10-Q | -32,656,000 | -0.99 | 125,690,000 | 88,115,000 | |
| 2024-12-31 | 10-Q | -98,300,000 | 146,942,000 | 116,842,000 | ||
| 2024-12-31 | 10-K | -98,333,000 | -3.09 | 146,942,000 | 116,842,000 | |
| 2024-09-30 | 10-Q | -29,489,000 | -0.89 | 173,865,000 | 139,326,000 | |
| 2024-06-30 | 10-Q | -21,238,000 | -0.64 | 192,007,000 | 164,948,000 | |
| 2024-03-31 | 10-Q | -21,682,000 | -0.77 | 213,205,000 | 182,950,000 | |
| 2023-12-31 | 10-K | -66,394,000 | -12.40 | 139,807,000 | 113,535,000 | |
| 2023-12-31 | 10-Q | -66,400,000 | 139,807,000 | 113,535,000 | ||
| 2023-09-30 | 10-Q | -20,108,000 | -12.36 | 54,724,000 | -162,808,000 | |
| 2023-06-30 | 10-Q | -13,441,000 | -8.30 | -143,619,000 | ||
| 2023-03-31 | 10-Q | -18,658,000 | -11.58 | -131,182,000 | ||
| 2022-12-31 | 10-Q | 59,277,000 | 97,076,000 | -112,954,000 | ||
| 2022-12-31 | 10-K | 654,000 | -59,277,000 | -36.36 | 97,076,000 | -112,954,000 |
| 2022-09-30 | 10-Q | 531,000 | -17,055,000 | -10.38 | -98,978,000 | |
| 2022-06-30 | 10-Q | -15,143,000 | -82,418,000 | |||
| 2022-03-31 | 10-Q | -12,502,000 | -67,829,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -55,000 | 5.69 | -313,137.00 | -1272,0% | |
| 2026-02-18 | Otero Jose Manuel | Officer, Chief Operating Officer | Open Market Sale | -3,016 | 6.40 | -19,293.96 | -78,4% | |
| 2026-02-18 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -10,173 | 6.38 | -64,924.09 | -263,7% | |
| 2025-11-18 | Adler Eric | Officer, Chief Medical Officer | Open Market Sale | -615 | 9.27 | -5,701.05 | -23,2% | |
| 2025-11-18 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -1,127 | 9.27 | -10,447.29 | -42,4% | |
| 2025-11-18 | Robertson Jenny | Officer, Chief Legal Officer | Open Market Sale | -549 | 9.27 | -5,089.23 | -20,7% | |
| 2025-11-18 | Otero Jose Manuel | Officer, Chief Operating Officer | Open Market Sale | -721 | 9.27 | -6,683.67 | -27,2% | |
| 2025-11-18 | See Tai Sandi | Officer, Chief Development Officer | Open Market Sale | -386 | 9.27 | -3,578.22 | -14,5% | |
| 2025-10-17 | Robertson Jenny | Officer, Chief Legal Officer | Open Market Sale | -40 | 9.56 | -382.44 | -1,6% | |
| 2025-10-17 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -148 | 9.56 | -1,415.03 | -5,7% | |
| 2025-10-17 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -12,985 | 8.94 | -116,020.98 | -471,3% | |
| 2025-10-17 | Otero Jose Manuel | Officer, Chief Technical Officer | Open Market Sale | -24 | 9.56 | -229.46 | -0,9% | |
| 2025-10-17 | Otero Jose Manuel | Officer, Chief Technical Officer | Open Market Sale | -2,091 | 8.94 | -18,683.09 | -75,9% | |
| 2025-10-17 | Robertson Jenny | Officer, Chief Legal Officer | Open Market Sale | -3,486 | 8.94 | -31,147.41 | -126,5% | |
| 2025-10-17 | Adler Eric | Officer, Chief Medical Officer | Open Market Sale | -38 | 9.56 | -363.32 | -1,5% | |
| 2025-10-17 | Adler Eric | Officer, Chief Medical Officer | Open Market Sale | -3,344 | 8.94 | -29,878.64 | -121,4% | |
| 2025-10-17 | See Tai Sandi | Officer, Chief Development Officer | Open Market Sale | -44 | 9.56 | -420.68 | -1,7% | |
| 2025-10-17 | See Tai Sandi | Officer, Chief Development Officer | Open Market Sale | -3,844 | 8.94 | -34,346.14 | -139,5% | |
| 2025-08-18 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -1,115 | 4.67 | -5,204.82 | -21,1% | |
| 2025-08-18 | Otero Jose Manuel | Officer, Chief Technical Officer | Open Market Sale | -2,848 | 4.67 | -13,294.46 | -54,0% | |
| 2025-08-18 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -2,735 | 4.67 | -12,766.98 | -51,9% | |
| 2025-08-18 | See Tai Sandi | Officer, Chief Development Officer | Open Market Sale | -382 | 4.67 | -1,783.18 | -7,2% | |
| 2025-08-18 | Otero Jose Manuel | Officer, Chief Technical Officer | Open Market Sale | -721 | 9.27 | -6,683.67 | -27,2% | |
| 2025-08-18 | Adler Eric | Officer, Chief Medical Officer | Open Market Sale | -608 | 4.67 | -2,838.14 | -11,5% | |
| 2025-08-18 | Robertson Jenny | Officer, Chief Legal Officer | Open Market Sale | -542 | 4.67 | -2,530.06 | -10,3% | |
| 2025-05-16 | See Tai Sandi | Officer, Chief Development Officer | Open Market Sale | -367 | 2.77 | -1,018.06 | -4,1% | |
| 2025-05-16 | Robertson Jenny | Officer, Chief Legal Officer | Open Market Sale | -521 | 2.77 | -1,445.25 | -5,9% | |
| 2025-05-16 | Townsend Richard Nolan | Director, Officer, Chief Executive Officer | Open Market Sale | -1,074 | 2.77 | -2,979.28 | -12,1% | |
| 2025-05-16 | Adler Eric | Officer, Chief Medical Officer | Open Market Sale | -585 | 2.77 | -1,622.79 | -6,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.